Navegar por autor "Lavilla Rubira, Esperanza"

Mostrando ítems 1-15 de 15

A personalized medicine ex vivo test to predict clinical response to first line induction therapy with idarubicin and cytarabine in patients with acute myeloid leukemia

2013- Lavilla Rubira, Esperanza
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

2023- Sargas, C.; Ayala, R.; Larráyoz, M.J.; Chillón, M.C.; Rodriguez-Arboli, E.; [et al.]
Ex vivo pharmacological evaluation of 16 drugs in 60+ acute myeloid leukemia patients using whole bone marrow samples analyzed by automated flow cytometry

2013- Lavilla Rubira, Esperanza
High correlation between clinical responses to 1st line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by exvitech

2014- Lavilla Rubira, Esperanza
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

2023- Sargas, C.; Ayala, R.; Larráyoz, M.J.; Chillón, M.C.; Carrillo-Cruz, E.; [et al.]
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

2023- Salmanton-García, J.; Marchesi, F.; Koehler, P.; Weinbergerová, B.; ?olovi?, N.; [et al.]
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

2024- Martínez-Cuadrón, D.; Megías-Vericat, J.E.; Gil, C.; Bernal, T.; Tormo, M.; [et al.]
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

2023- Marchesi, F.; Salmanton-García, J.; Buquicchio, C.; Itri, F.; Besson, C.; [et al.]
Personalizing therapies with ex vivo pharmacological responses may uncover the differences between IDA-DNR-MIT among european AML protocols

2013- Lavilla Rubira, Esperanza
Pharmacological profile of cytarabine and idarubicin in patient samples (ex vivo) with newly diagnosed acute myeloid leukemia identifies responders vs non responders

2013- Lavilla Rubira, Esperanza
Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine

2014- Lavilla Rubira, Esperanza
Pharmacological profiles of AML treatments in patient samples to personalize treatment.

2014- Fernandez Fernandez, Angeles; Lavilla Rubira, Esperanza
Population pharmacological profiles of aml treatments in patient samples by automated flow cytometry; a bridge to individualized medicine

2013- Lavilla Rubira, Esperanza